Patents by Inventor Sandra Verploegen

Sandra Verploegen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN IGG1 FC REGION VARIANTS AND USES THEREOF
    Publication number: 20250145720
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the poly-peptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).
    Type: Application
    Filed: June 14, 2024
    Publication date: May 8, 2025
    Inventors: Paul PARREN, Frank BEURSKENS, Rob N. DE JONG, Sandra VERPLOEGEN, Aran Frank LABRIJN, Janine SCHUURMAN
  • Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
    Patent number: 12246025
    Abstract: The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: March 11, 2025
    Assignee: Genmab A/S
    Inventors: Reshma Abdulla Rangwala, Esther C. W. Breij, Sandra Verploegen, Oyewale O. Abidoye, Leonardo Viana Nicacio
  • METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
    Publication number: 20250066507
    Abstract: The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
    Type: Application
    Filed: August 8, 2024
    Publication date: February 27, 2025
    Inventors: Reshma Abdulla RANGWALA, Esther C.W. BREIJ, Sandra VERPLOEGEN, OyewaleV O. ABIDOYE, Leonardo Viana NICACIO, Anthony CAO, Shyra GARDAI
  • HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR
    Publication number: 20240294661
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Application
    Filed: December 1, 2023
    Publication date: September 5, 2024
    Inventors: David SATIJN, Sandra VERPLOEGEN, Wim BLEEKER, Steen LISBY, Jan VAN DE WINKEL, Patrick VAN BERKEL, Paul PARREN
  • HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF
    Publication number: 20230416403
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: December 6, 2022
    Publication date: December 28, 2023
    Inventors: Sandra VERPLOEGEN, David P. E. SATIJN, Rene M. A. HOET, Paul PARREN, Jan VAN DE WINKEL, Vibeke Miller BREINHOLT, Eva EHRNROOTH, Ole BAADSGAARD, Tom VINK, Willem Karel BLEEKER, Mischa HOUTKAMP, Maroeska OUDSHOORN, Rob N. DE JONG
  • METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
    Publication number: 20230027495
    Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
    Type: Application
    Filed: November 6, 2020
    Publication date: January 26, 2023
    Applicants: Genmab A/S, MSD International GmbH
    Inventors: Reshma Abdulla RANGWALA, Esther C.W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo Viana NICACIO, Anthony CAO, Shyra GARDAI
  • METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
    Publication number: 20220387485
    Abstract: The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.
    Type: Application
    Filed: November 6, 2020
    Publication date: December 8, 2022
    Applicant: Genmab A/S
    Inventors: Reshma A RANGWALA, Esther C,W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo V. NICACIO
  • HUMAN ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AGAINST CD74
    Publication number: 20220323582
    Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.
    Type: Application
    Filed: October 15, 2021
    Publication date: October 13, 2022
    Inventors: Sandra VERPLOEGEN, Marije OVERDIJK, Riemke VAN DIJKHUIZEN, Willem Karel BLEEKER, Patrick VAN BERKEL, Paul PARREN, Steen LISBY
  • METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
    Publication number: 20220088191
    Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
    Type: Application
    Filed: May 7, 2019
    Publication date: March 24, 2022
    Applicants: MSD International GmbH
    Inventors: Reshma Abdulla RANGWALA, Esther C.W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo Viana NICACIO, Anthony CAO, Shyra GARDAI
  • METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-VEGF ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
    Publication number: 20210402003
    Abstract: The invention provides an anti-VEGF antibody (e.g., bevacizumab) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such cervical cancer. The invention also provides compositions and kits comprising the anti-VEGF antibody (e.g., bevacizumab) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as cervical cancer.
    Type: Application
    Filed: October 28, 2019
    Publication date: December 30, 2021
    Applicant: Genmab A/S
    Inventors: Reshma Abdulla RANGWALA, Sandra VERPLOEGEN, Esther C.W. BREIJ, Oyewale O. ABIDOYE, Leonardo Viana NICACIO
  • HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR
    Publication number: 20210395384
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Application
    Filed: March 10, 2021
    Publication date: December 23, 2021
    Inventors: David SATJIN, Sandra VERPLOEGEN, Wim BLEEKER, Steen LISBY, Jan VAN DE WINKEL, Patrick VAN BERKEL, Paul PARREN
  • Dimeric protein with triple mutations
    Patent number: 11180572
    Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: November 23, 2021
    Assignee: GENMAB B.V.
    Inventors: Rob N. De Jong, Frank Beurskens, Paul Parren, Aran Frank Labrijn, Janine Schuurman, Arjen Vlug, Sandra Verploegen
  • ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
    Publication number: 20210308208
    Abstract: The invention provides methods and compositions for treating cancer, such as ovarian cancer, peritoneal cancer, and fallopian tube cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., ovarian cancer, peritoneal cancer, and fallopian tube cancer).
    Type: Application
    Filed: August 14, 2019
    Publication date: October 7, 2021
    Inventors: Reshma A. RANGWALA, Esther C.W. BREIJ, Sandra VERPLOEGEN, Bart DE GOEIJ, Oyewale O. ABIDOYE, Leonardo V. NICACIO, Stephen C. ALLEY
  • DIMERIC PROTEIN WITH TRIPLE MUTATIONS
    Publication number: 20210230301
    Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.
    Type: Application
    Filed: September 4, 2020
    Publication date: July 29, 2021
    Inventors: Rob N. DE JONG, Frank BEURSKENS, Paul PARREN, Aran Frank LABRIJN, Janine SCHUURMAN, Arjen VLUG, Sandra VERPLOEGEN
  • HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF
    Publication number: 20210171657
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: May 21, 2020
    Publication date: June 10, 2021
    Applicants: GENMAB A/S, GENMAB A/S
    Inventors: Sandra VERPLOEGEN, David P.E. SATIJN, Rene M.A. HOET, Paul PARREN, Jan VAN DE WINKEL, Vibeke Miller BREINHOLT, Eva EHRNROOTH, Ole BAADSGAARD, D.M.Sc., Tom VINK, Willem Karel BLEEKER, Mischa HOUTKAMP, Maroeska OUDSHOORN, Rob N. DE JONG
  • METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
    Publication number: 20210107980
    Abstract: The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
    Type: Application
    Filed: May 7, 2019
    Publication date: April 15, 2021
    Inventors: Reshma Abdulla RANGWALA, Esther C.W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo Viana NICACIO, Anthony CAO, Shyra GARDAI
  • ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
    Publication number: 20210030888
    Abstract: The invention provides methods and compositions for treating cancer, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer).
    Type: Application
    Filed: March 6, 2019
    Publication date: February 4, 2021
    Inventors: Reshma Abdulla RANGWALA, Esther Cornelia Wilhelmina BREIJ, David SATIJN, Sandra VERPLOEGEN, Jantine BAKEMA, Oyewale O. ABIDOYE, Leonardo Viana NICACIO, Andreas LINGNAU
  • METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
    Publication number: 20210015939
    Abstract: The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.
    Type: Application
    Filed: March 20, 2019
    Publication date: January 21, 2021
    Inventors: Reshma Abdulla RANGWALA, Esther C.W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo Viana NICACIO
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
    Publication number: 20200199231
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Application
    Filed: December 4, 2019
    Publication date: June 25, 2020
    Inventors: Patrick ENGELBERTS, Esther BREIJ, Rik RADEMAKER, Isil ALTINTAS, David SATIJN, Sandra VERPLOEGEN, Riemke VAN DIJKHUIZEN RADERSMA, Edward VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
  • Bispecific antibodies against CD3 and CD20
    Patent number: 10544220
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 28, 2020
    Assignee: GENMAB A/S
    Inventors: Patrick Engelberts, Esther Breij, Rik Rademaker, Isil Altintas, David Satijn, Sandra Verploegen, Riemke Van Dijkhuizen Radersma, Edward Van Den Brink, Janine Schuurman, Paul Parren